What a compounded prescription means

What does compounding add to the plan?

The compounder prepares the drug around a patient’s needs. It is an alternative to dispensing the finished product from a manufacturer. FDA’s account recorded September 17, 2026 describes needs such as a problem with an ingredient in an available product.

The FDA check dated November 3, 2026 found the approval distinction unchanged. Compounded drugs reach sale without an FDA review of their benefit, quality, and safety.

Ask why the proposed drug is needed for you and which approved options were considered. This is a question about the clinical proposal. A lower price alone does not explain what is different about the medicine.

What do the pharmacy categories tell you?

The section 503A route ties the drug to a valid prescription naming a patient. A licensed doctor or a pharmacist in a state-licensed pharmacy makes it. Other conditions also apply. That account was checked November 3, 2026.

Section 503B covers facilities that elect to register with FDA for sterile compounding, the making of drugs without living germs. Under the rules checked November 3, 2026, they can supply without patient-specific prescriptions and must follow federal manufacturing standards.

Neither category makes the drugs FDA-approved. State pharmacy boards provide the main day-to-day oversight for ordinary state pharmacies; FDA has primary oversight of registered outsourcing facilities, in the account recorded September 17, 2026.

Did the October draft approve peptides?

No. The October 30, 2026 draft came from HHS, the federal health department. Under its stated conditions, HHS said it planned no enforcement action over certain individual patients’ prescriptions compounded by doctors or state-licensed pharmacies. Its peptide list includes KPV, epitalon, BPC-157, semax, TB-500, and MOTS-c.

The draft applies only to a medicine with one active ingredient. It limits which ingredient forms and ways of giving the medicine qualify. Blends are outside the policy, as are the larger compounders called section 503B outsourcing facilities. The draft gives no FDA approval. In the record checked November 3, 2026, none of these six appears on the 503A bulks list, FDA’s official list of extra raw ingredients allowed for patient-specific compounding.

This is an enforcement plan: the agency describes circumstances in which it plans not to act. It is a draft, is not binding, and gives no right to compound. A medicine made under the policy still lacks FDA approval. These limits were checked November 3, 2026. HHS may change its approach if safety or quality concerns arise.

Ask the service which exact drug it proposes and which conditions it relies on. A headline about a peptide does not answer whether a specific blend or route fits the draft.

What if the proposal copies an available drug?

The federal rule review dated November 3, 2026 found that routinely making near-copies of available drugs faces limits. Large-volume copying faces limits too. For a change for a named patient, the prescriber must decide what makes a significant difference for that person.

FDA’s supply update checked November 3, 2026 says semaglutide and tirzepatide are absent from the national shortage list. Stock missing from a local shelf is not a national shortage record.

Adding a vitamin does not automatically remove the copy issue, according to FDA’s policy record checked November 3, 2026. Ask for the actual patient-specific rationale rather than assuming a changed ingredient list settles it.

Keep the compounding rules beside the price discussion. A quote may give a clear price while leaving care and rule questions open. The research notes give the dated policy context, including what a committee vote does and does not change.